“3 Key Trends” With Mahesh Bhalgat
Syngene Eyes Sweet Spot As New Modalities Hog Limelight
Syngene CEO On Sub-Dynamics As US Biotech Funding Finds New Normal, ADC Capabilities :: Scrip (citeline.com)
Intellectual partnerships, Smaller biotech firms as innovation hubs and ESG considerations encouraging sustainable practices in the pharmaceutical industry
Navigating the Pharma Landscape
CRDMOs in India to create local supply eco-system, asserts itself as a bio-pharma sourcing powerhouse
The nitty gritty of biotherapeutics production
Syngene expects outsourcing boost from West
CDMOs will play a vital role in bringing CGT and mRNA technologies to market
Indian CDMOs now scout for capital-intensive projects and invest in new technologies for global orders
